5.77
price down icon6.18%   -0.38
pre-market  Pre-market:  5.37   -0.40   -6.93%
loading
Y Mabs Therapeutics Inc stock is traded at $5.77, with a volume of 888.68K. It is down -6.18% in the last 24 hours and down -16.26% over the past month. Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
See More
Previous Close:
$6.15
Open:
$6.08
24h Volume:
888.68K
Relative Volume:
2.32
Market Cap:
$258.43M
Revenue:
$84.82M
Net Income/Loss:
$-21.43M
P/E Ratio:
-11.78
EPS:
-0.49
Net Cash Flow:
$-27.23M
1W Performance:
-3.83%
1M Performance:
-16.26%
6M Performance:
-48.53%
1Y Performance:
-55.99%
1-Day Range:
Value
$5.65
$6.21
1-Week Range:
Value
$5.65
$6.33
52-Week Range:
Value
$5.65
$20.90

Y Mabs Therapeutics Inc Stock (YMAB) Company Profile

Name
Name
Y Mabs Therapeutics Inc
Name
Phone
212-847-9841
Name
Address
230 PARK AVENUE, NEW YORK, NY
Name
Employee
100
Name
Twitter
Name
Next Earnings Date
2024-11-08
Name
Latest SEC Filings
Name
YMAB's Discussions on Twitter

Compare YMAB with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
YMAB
Y Mabs Therapeutics Inc
5.77 258.43M 84.82M -21.43M -27.23M -0.49
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
455.22 117.23B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
665.46 72.75B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
636.02 38.65B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.99 34.69B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
114.50 27.45B 3.30B -501.07M 1.03B -2.1146

Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades

Date Action Analyst Rating Change
Nov-18-24 Initiated Oppenheimer Outperform
Aug-16-24 Initiated Cantor Fitzgerald Overweight
Jun-28-24 Initiated Truist Buy
May-10-23 Upgrade Wedbush Neutral → Outperform
Apr-03-23 Downgrade Guggenheim Buy → Neutral
Jan-27-23 Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-23 Downgrade Cowen Outperform → Market Perform
Dec-02-22 Downgrade BofA Securities Buy → Neutral
Oct-31-22 Downgrade JP Morgan Neutral → Underweight
Oct-31-22 Downgrade Wedbush Outperform → Neutral
Jul-06-22 Resumed Canaccord Genuity Buy
Jun-24-22 Initiated BMO Capital Markets Outperform
Feb-03-22 Resumed Guggenheim Buy
Nov-19-21 Resumed Morgan Stanley Equal-Weight
Nov-16-21 Downgrade JP Morgan Overweight → Neutral
May-07-21 Upgrade BofA Securities Neutral → Buy
Apr-23-21 Resumed Cowen Outperform
Mar-22-21 Resumed JP Morgan Overweight
Jan-15-21 Downgrade BofA Securities Buy → Neutral
Nov-09-20 Reiterated H.C. Wainwright Buy
May-05-20 Initiated Barclays Overweight
May-01-20 Initiated Janney Buy
Apr-29-20 Initiated Morgan Stanley Equal-Weight
Dec-24-19 Initiated JP Morgan Overweight
Nov-20-19 Initiated Guggenheim Buy
Sep-04-19 Initiated Wedbush Outperform
Apr-01-19 Initiated H.C. Wainwright Buy
Oct-16-18 Initiated BTIG Research Buy
Oct-16-18 Initiated BofA/Merrill Buy
View All

Y Mabs Therapeutics Inc Stock (YMAB) Latest News

pulisher
Feb 11, 2025

YMAB Stock Touches 52-Week Low at $5.69 Amid Market Challenges - MSN

Feb 11, 2025
pulisher
Feb 10, 2025

When the Price of (YMAB) Talks, People Listen - Stock Traders Daily

Feb 10, 2025
pulisher
Feb 08, 2025

After Falling -15.24% During The Past Week, Should You Still Buy Oruka Therapeutics Inc (NASDAQ: ORKA)? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Y-Mabs Therapeutics Inc (NASDAQ: YMAB) Stock Has Dropped -21.18% Over The Month – Is There Room For Growth? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Mineralys Therapeutics Inc (NASDAQ: MLYS): Can The Stock Still Lose Despite An -20.31% YTD Loss? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Now Is The Time To Build A Position In Health In Tech Inc (NASDAQ:HIT) - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Should You Expect Akero Therapeutics Inc (NASDAQ:AKRO) To Recover From Its 70.02% Gain From Highs? - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

ScanTech AI Systems Inc (NASDAQ: STAI) Gain Of 9.66% Compared To 52-Week Low; YTD Fall -84.49% – What Should You Do Now? – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Apogee Therapeutics Inc (NASDAQ: APGE) Recovered 16.57% From The 52-Week Low, And Now It’s -12.32% YTD – This Is What You Do Now – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 08, 2025

Now Is The Time To Build A Position In SolarBank Corporation (NASDAQ:SUUN) - Marketing Sentinel

Feb 08, 2025
pulisher
Feb 07, 2025

Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace

Feb 07, 2025
pulisher
Feb 06, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Buy" by Brokerages - MarketBeat

Feb 06, 2025
pulisher
Feb 06, 2025

Y-Mabs Therapeutics Inc (YMAB) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News

Feb 06, 2025
pulisher
Feb 06, 2025

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference - The Manila Times

Feb 06, 2025
pulisher
Feb 06, 2025

Cancer Treatment Pioneer Y-mAbs Takes Center Stage at Major Healthcare Conference - StockTitan

Feb 06, 2025
pulisher
Feb 04, 2025

YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - MSN

Feb 04, 2025
pulisher
Feb 04, 2025

Analytical Overview: Y-Mabs Therapeutics Inc (YMAB)’s Ratios Tell a Financial Story - The Dwinnex

Feb 04, 2025
pulisher
Feb 04, 2025

An Overview of Castellum Inc (AMEX: CTM)’s Stock Performance and Outlook - Marketing Sentinel

Feb 04, 2025
pulisher
Feb 04, 2025

A stock that deserves closer examination: Y-Mabs Therapeutics Inc (YMAB) - US Post News

Feb 04, 2025
pulisher
Feb 04, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World

Feb 04, 2025
pulisher
Feb 04, 2025

Let’s Jump Into The SolarBank Corporation (NASDAQ: SUUN) Stock Forecast - Marketing Sentinel

Feb 04, 2025
pulisher
Feb 03, 2025

YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance

Feb 03, 2025
pulisher
Feb 01, 2025

YMAB stock touches 52-week low at $6 amid challenging year - MSN

Feb 01, 2025
pulisher
Jan 31, 2025

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - The Manila Times

Jan 31, 2025
pulisher
Jan 31, 2025

Groundbreaking Cancer Treatment Data: Y-mAbs' GD2-SADA Shows Remarkable Preclinical Results - StockTitan

Jan 31, 2025
pulisher
Jan 30, 2025

Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - MSN

Jan 30, 2025
pulisher
Jan 30, 2025

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co. - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

Y-mAbs Therapeutics’ SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Nigeria

Jan 29, 2025
pulisher
Jan 29, 2025

(YMAB) Trading Report - Stock Traders Daily

Jan 29, 2025
pulisher
Jan 24, 2025

Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha

Jan 24, 2025
pulisher
Jan 23, 2025

Cantor Fitzgerald Weighs in on YMAB FY2025 Earnings - Defense World

Jan 23, 2025
pulisher
Jan 22, 2025

Cantor Fitzgerald Predicts YMAB FY2025 Earnings - MarketBeat

Jan 22, 2025
pulisher
Jan 20, 2025

Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World

Jan 20, 2025
pulisher
Jan 17, 2025

Now Is The Time To Build A Position In NewGenIvf Group Ltd (NASDAQ:NIVF) - Marketing Sentinel

Jan 17, 2025
pulisher
Jan 16, 2025

XORTX Therapeutics Inc (NASDAQ:XRTX) Plunging -39.23% In 6 Months – Here’s What To Expect - Marketing Sentinel

Jan 16, 2025
pulisher
Jan 15, 2025

Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World

Jan 15, 2025
pulisher
Jan 15, 2025

Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World

Jan 15, 2025
pulisher
Jan 14, 2025

Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks

Jan 13, 2025
pulisher
Jan 13, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World

Jan 12, 2025
pulisher
Jan 12, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance

Jan 11, 2025
pulisher
Jan 10, 2025

Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet - Simply Wall St

Jan 10, 2025
pulisher
Jan 10, 2025

Correcting & ReplacingY-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Reports $88M Revenue, Restructures with Focus on Radiopharmaceuticals and DANYELZA Growth - StockTitan

Jan 10, 2025
pulisher
Jan 10, 2025

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - Business Upturn

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Therapeutics, Inc. Announces Executive Changes - Marketscreener.com

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Appoints Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit - citybiz

Jan 10, 2025
pulisher
Jan 10, 2025

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - The Manila Times

Jan 10, 2025

Y Mabs Therapeutics Inc Stock (YMAB) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$79.89
price up icon 2.27%
$32.25
price up icon 1.67%
$4.47
price down icon 5.10%
$353.31
price up icon 2.22%
biotechnology ONC
$221.22
price up icon 0.71%
$114.50
price down icon 0.67%
Cap:     |  Volume (24h):